Alzheimer’s Drugs Market Outlook: Growth and Forecast Highlights 2030

Uncover key drivers, emerging technologies, and competitive movements shaping the alzheimer’s drugs market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Alzheimer’s Drugs Market from 2026 to 2030?

The alzheimer’s drugs market has shown robust expansion over recent years. It is anticipated to grow from $10.09 billion in 2025 to $10.99 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.9%. The historical growth of this market can be ascribed to an increasing elderly population, the rising prevalence of Alzheimer’s disease, growing awareness of dementia care, limited treatment options available in early years, and advancements in neuroscience research.

The alzheimer’s drugs market is projected to experience substantial expansion in the coming years. This market is forecast to reach $15.4 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.8%. The anticipated growth during this period is largely driven by developments in precision medicine, the incorporation of AI into drug discovery, the broadening of healthcare infrastructure, governmental aid and funding for dementia research, and the rise of digital health monitoring solutions. Key trends expected over the forecast horizon encompass the creation of personalized Alzheimer’s treatments, breakthroughs in neuroprotective medications, advanced solutions for early diagnosis and screening, the development of combination and multi-target drugs, and systems for enhancing patient adherence and monitoring.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9040&type=smp

What Drivers Are Affecting Demand In The Alzheimer’s Drugs Market?

The escalating incidence of Alzheimer’s disease is projected to stimulate the expansion of the Alzheimer’s drugs market in the coming years. This neurological condition progressively worsens, resulting in brain atrophy and the death of brain cells. Medications for Alzheimer’s disease are employed to address memory impairment, cognitive difficulties, and challenges in daily living. These treatments can enhance the quality of life for patients and assist in preserving their independence. For example, in May 2024, a report by the Alzheimer’s Association, a US-based nonprofit organization dedicated to Alzheimer’s care, support, and research, revealed that the number of Americans aged 65 and older diagnosed with Alzheimer’s dementia grew from 6.5 million in 2022 to an estimated 6.9 million in 2024. Thus, the rising occurrence of Alzheimer’s disease is a key factor propelling the growth of the Alzheimer’s drugs market.

Which Segments Are Gaining Traction In The Alzheimer’s Drugs Market?

The alzheimer’s drugs market covered in this report is segmented –

1) By Drugs: Donepezil, Rivastigmine, Galantamine, Memantine

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3) By Application: Early To Moderate Stages, Moderate To Severe Stages

How Are New Market Trends Shaping The Landscape Of The Alzheimer’s Drugs Market?

Leading companies in the Alzheimer’s drugs market are developing innovative products, such as amyloid plaque-targeting therapy, to advance treatment options and improve patient outcomes. Amyloid plaque-targeting therapy is a therapeutic approach for Alzheimer’s disease focused on reducing or preventing the accumulation of amyloid-beta plaques in the brain. For instance, in June 2024, Eli Lilly and Company, a US-based pharmaceutical company, secured approval for Kisunla (donanemab-azbt) from the Food and Drug Administration (FDA), a US-based federal agency tasked with protecting public health. Kisunla (donanemab-azbt) is the sole and initial amyloid plaque-targeting therapy for early symptomatic Alzheimer’s disease. It operates by assisting the body in removing excess amyloid plaques from the brain, which are linked to cognitive decline in Alzheimer’s patients. Kisunla is administered as an intravenous infusion every four weeks. The initial dosing regimen involves 700 mg for the first three doses, followed by 1400 mg thereafter. Kisunla is specifically indicated for adults with mild cognitive impairment (MCI) and mild dementia stages of Alzheimer’s disease, provided they have confirmed amyloid pathology.

Who Are The Major Companies Operating In The Alzheimer’s Drugs Market?

Major companies operating in the alzheimer’s drugs market are AbbVie Inc., Daiichi Sankyo Company Limited, F Hoffmann-La Roche AG, Merck & Co Inc., Novartis AG, Biogen Inc., AstraZeneca PLC, Eisai Co Ltd., Eli Lilly and Company, H Lundbeck A/S, Pfizer Inc., Allergan PLC, Johnson & Johnson, Lupin Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Neurotrope Inc., AC Immune SA, Adamas Pharmaceuticals Inc, Alzheon Inc., Anavex Life Sciences Corp, Axsome Therapeutics Inc., Cassava Sciences Inc., Cognition Therapeutics Inc., Cortexyme Inc., Denali Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Alzheimer’s Drugs Market?

North Americawas the largest region in the Alzheimer’s drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the Alzheimer’s drugs market during the forecast period. The regions covered in the alzheimer’s drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Alzheimer’s Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9040&type=smp

Browse Through More Reports Similar to the Global Alzheimer’s Drugs Market 2026, By The Business Research Company

Alzheimers Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

Alzheimers Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

Neurological Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795